Low-dose nivolumab for advanced cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Digestive system, Immune system & allergy, Infections, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests a lower, less frequent dose of an immunotherapy drug called nivolumab for people with certain advanced cancers. The goal is to see if a reduced dose can still control cancer while causing fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of several specific cancer types (like lung, head and neck, kidney, melanoma, lymphoma, or others) that have spread or cannot be removed by surgery.
- For some cancers, you need a special test result showing your tumor has a marker called PD-L1.
- You must have tried treatment and it didn't work, or you are not a good candidate for existing curative treatments.
- You must have at least one tumor that can be measured on a scan.
- You must be 18 or older and able to give informed consent.
- You must have adequate kidney, liver, and blood cell counts, and not have any serious infections or autoimmune conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining two immunotherapy medicines—cabozantinib and nivolumab—can shrink advanced melanoma or certain head-and-neck squamous cell cancers. It is mainly for people whose cancer has grown after prior PD-1 treatment.
This study compares giving the immunotherapy drug nivolumab as a shot under the skin at home versus in the clinic. It is for people with certain cancers who are already taking or starting nivolumab.
This Phase 1 trial tests a new combination of PBF-1129 with nivolumab (an immune therapy) for lung cancer that has come back or spread. It aims to find a safe dose and see whether the combination can shrink tumors and improve outcomes.
This trial tests a new combination of drugs (axelopran and nivolumab) for people with advanced melanoma that stopped responding to earlier immunotherapy. The goal is to see if this combination can help your immune system fight the cancer again.
This trial studies nivolumab, an immune therapy, for skin squamous cell cancer that can’t be cured with surgery or radiation. It aims to see how well the treatment shrinks tumors and helps people live longer or longer without cancer growth.
This study tests a lower dose of immunotherapy in patients with colorectal or stomach cancer that has spread or cannot be removed by surgery. The cancer must have a specific genetic feature (MSI/dMMR). The goal is to see if this approach works well with fewer side effects.
Hear when a new Clinical Stage III Cutaneous Melanoma AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.